Details
| Stereochemistry | MIXED |
| Molecular Formula | C24H32N2O2.2ClH |
| Molecular Weight | 453.445 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CCOC(CN1CCN(CC(C)C(=O)C2=CC=CC=C2)CC1)C3=CC=CC=C3
InChI
InChIKey=BPMQVOKMMQFZGV-UHFFFAOYSA-N
InChI=1S/C24H32N2O2.2ClH/c1-3-28-23(21-10-6-4-7-11-21)19-26-16-14-25(15-17-26)18-20(2)24(27)22-12-8-5-9-13-22;;/h4-13,20,23H,3,14-19H2,1-2H3;2*1H
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=421 | http://en.pharmacodia.com/web/drug/1_11802.html
Curator's Comment: description was created based on several sources, including:
http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=421 | http://en.pharmacodia.com/web/drug/1_11802.html
Eprazinone has been variously described as having mucolytic or expectorant properties as well as a direct relaxant action on bronchial smooth muscle and it suppress the excitation of cough center to stop coughing. It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia The most commonly reported adverse reactions include loss of appetite, nausea/vomiting, stomach discomfort, diarrhea (including loose stool) and symptom of irritation.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL249 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24849814 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Eftapan Approved UseIt is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia |
|||
| Palliative | Eftapan Approved UseIt is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia |
|||
| Palliative | Eftapan Approved UseIt is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia. |
|||
| Palliative | Eftapan Approved UseIt is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia. |
Sample Use Guides
take 60-90mg of the active ingredient in 3 divided doses a day
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24849814
Eprazinone displayed a rather weak inhibition of [125I]BH-SPbinding to NK1R, at a concentration of 25 uM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity or could even be a hint to a still unrevealed mode of action.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
73356
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
m4958
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID1046631
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
100000092366
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
31551
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
SUB01919MIG
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
394X1L8I9Y
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
236310
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | RxNorm | ||
|
C007608
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
233-872-8
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
317935
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
10402-53-6
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
DBSALT001085
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY | |||
|
CHEMBL1885437
Created by
admin on Mon Mar 31 17:53:52 GMT 2025 , Edited by admin on Mon Mar 31 17:53:52 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD